349 related articles for article (PubMed ID: 25003290)
1. Risk factors for bowel dysfunction after sphincter-preserving rectal cancer surgery: a prospective study using the Memorial Sloan Kettering Cancer Center bowel function instrument.
Ihn MH; Kang SB; Kim DW; Oh HK; Lee SY; Hong SM
Dis Colon Rectum; 2014 Aug; 57(8):958-66. PubMed ID: 25003290
[TBL] [Abstract][Full Text] [Related]
2. Predictive Factors for Bowel Dysfunction After Sphincter-Preserving Surgery for Rectal Cancer: A Single-Center Cross-sectional Study.
Park YY; Yang SY; Han YD; Cho MS; Hur H; Min BS; Lee KY; Kim NK
Dis Colon Rectum; 2019 Aug; 62(8):925-933. PubMed ID: 30855308
[TBL] [Abstract][Full Text] [Related]
3. The development of a validated instrument to evaluate bowel function after sphincter-preserving surgery for rectal cancer.
Temple LK; Bacik J; Savatta SG; Gottesman L; Paty PB; Weiser MR; Guillem JG; Minsky BD; Kalman M; Thaler HT; Schrag D; Wong WD
Dis Colon Rectum; 2005 Jul; 48(7):1353-65. PubMed ID: 15868235
[TBL] [Abstract][Full Text] [Related]
4. Complications after sphincter-saving resection in rectal cancer patients according to whether chemoradiotherapy is performed before or after surgery.
Kim CW; Kim JH; Yu CS; Shin US; Park JS; Jung KY; Kim TW; Yoon SN; Lim SB; Kim JC
Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):156-63. PubMed ID: 20106604
[TBL] [Abstract][Full Text] [Related]
5. Analysis of bevacizumab-based preoperative radiochemotherapy in patients with locally advanced rectal cancer on surgery-associated spectrum of complications.
Dellas K; Buller J; Görtz GJ; Richter M; Höhler T; Arnold D; Keck T; Dunst J; Zühlke H
Ann Surg Oncol; 2014 Apr; 21(4):1352-60. PubMed ID: 24306667
[TBL] [Abstract][Full Text] [Related]
6. Cumulative incidence of permanent stoma after sphincter preserving low anterior resection of mid and low rectal cancer.
Dinnewitzer A; Jäger T; Nawara C; Buchner S; Wolfgang H; Öfner D
Dis Colon Rectum; 2013 Oct; 56(10):1134-42. PubMed ID: 24022530
[TBL] [Abstract][Full Text] [Related]
7. [Evaluation of preoperative radiotherapy or chemoradiotherapy in sphincter preservation for locally advanced middle-low rectal cancer].
Cao WG; Zhao R; Xi WQ; Ma T; Li H; Xu HP; Che JF; Jin YN
Zhonghua Zhong Liu Za Zhi; 2007 Mar; 29(3):225-7. PubMed ID: 17649643
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of neoadjuvant chemoradiotherapy with oxaliplatin and capecitabine for rectal cancer.
Zhao L; Bai C; Shao Y; Guan M; Jia N; Xiao Y; Qiu H; Zhang F; Yang T; Zhong G; Chen S
Cancer Lett; 2011 Nov; 310(2):134-9. PubMed ID: 21782322
[TBL] [Abstract][Full Text] [Related]
9. A prospective pilot study of target-guided personalized chemotherapy with intensity-modulated radiotherapy in patients with early rectal cancer.
Cubillo A; Hernando-Requejo O; García-García E; Rodriguez-Pascual J; De Vicente E; Morelli P; Rubio C; López-Ríos F; Muro A; López U; Prados S; Quijano Y; Hidalgo M
Am J Clin Oncol; 2014 Apr; 37(2):117-21. PubMed ID: 23211222
[TBL] [Abstract][Full Text] [Related]
10. Bowel Dysfunction After Low Anterior Resection With Neoadjuvant Chemoradiotherapy or Chemotherapy Alone for Rectal Cancer: A Cross-Sectional Study from China.
Qin Q; Huang B; Cao W; Zhou J; Ma T; Zhou Z; Wang J; Wang L
Dis Colon Rectum; 2017 Jul; 60(7):697-705. PubMed ID: 28594719
[TBL] [Abstract][Full Text] [Related]
11. T3+ and T4 rectal cancer patients seem to benefit from the addition of oxaliplatin to the neoadjuvant chemoradiation regimen.
Martijnse IS; Dudink RL; Kusters M; Vermeer TA; West NP; Nieuwenhuijzen GA; van Lijnschoten I; Martijn H; Creemers GJ; Lemmens VE; van de Velde CJ; Sebag-Montefiore D; Glynne-Jones R; Quirke P; Rutten HJ
Ann Surg Oncol; 2012 Feb; 19(2):392-401. PubMed ID: 21792506
[TBL] [Abstract][Full Text] [Related]
12. Predicting the Risk of Bowel-Related Quality-of-Life Impairment After Restorative Resection for Rectal Cancer: A Multicenter Cross-Sectional Study.
Battersby NJ; Juul T; Christensen P; Janjua AZ; Branagan G; Emmertsen KJ; Norton C; Hughes R; Laurberg S; Moran BJ;
Dis Colon Rectum; 2016 Apr; 59(4):270-80. PubMed ID: 26953985
[TBL] [Abstract][Full Text] [Related]
13. Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer.
Cercek A; Roxburgh CSD; Strombom P; Smith JJ; Temple LKF; Nash GM; Guillem JG; Paty PB; Yaeger R; Stadler ZK; Seier K; Gonen M; Segal NH; Reidy DL; Varghese A; Shia J; Vakiani E; Wu AJ; Crane CH; Gollub MJ; Garcia-Aguilar J; Saltz LB; Weiser MR
JAMA Oncol; 2018 Jun; 4(6):e180071. PubMed ID: 29566109
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab-containing chemotherapy is safe in patients with unresectable metastatic colorectal cancer and a synchronous asymptomatic primary tumor.
Cetin B; Kaplan MA; Berk V; Tufan G; Benekli M; Isikdogan A; Ozkan M; Coskun U; Buyukberber S
Jpn J Clin Oncol; 2013 Jan; 43(1):28-32. PubMed ID: 23107836
[TBL] [Abstract][Full Text] [Related]
15. Pathological response of locally advanced rectal cancer to preoperative chemotherapy without pelvic irradiation.
Bensignor T; Brouquet A; Dariane C; Thirot-Bidault A; Lazure T; Julié C; Nordlinger B; Penna C; Benoist S
Colorectal Dis; 2015 Jun; 17(6):491-8. PubMed ID: 25524450
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial.
Chua YJ; Barbachano Y; Cunningham D; Oates JR; Brown G; Wotherspoon A; Tait D; Massey A; Tebbutt NC; Chau I
Lancet Oncol; 2010 Mar; 11(3):241-8. PubMed ID: 20106720
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant capecitabine and oxaliplatin (XELOX) combined with bevacizumab for high-risk localized rectal cancer.
Hasegawa J; Nishimura J; Mizushima T; Miyake Y; Kim HM; Takemoto H; Tamagawa H; Noura S; Fujii M; Fujie Y; Kato T; Miwa H; Takemasa I; Ikeda M; Yamamoto H; Sekimoto M; Nezu R; Doki Y; Mori M
Cancer Chemother Pharmacol; 2014 May; 73(5):1079-87. PubMed ID: 24595805
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant chemoradiotherapy with capecitabine followed by laparoscopic resection in locally advanced tumors of middle and low rectum - toxicity and complications of the treatment.
Soumarova R; Skrovina M; Bartos J; Gruna J; Wendrinski A; Czudek S; Kycina R; Parvez J
Eur J Surg Oncol; 2010 Mar; 36(3):251-6. PubMed ID: 19879716
[TBL] [Abstract][Full Text] [Related]
19. [A case report of pathologically complete response of locally advanced rectal cancer after neoadjuvant chemoradiotherapy with XELOX and bevacizumab].
Miyazawa T; Ebe K; Fujita N; Koide N; Honma K; Ikarashi T
Gan To Kagaku Ryoho; 2012 Jun; 39(6):1001-3. PubMed ID: 22705702
[TBL] [Abstract][Full Text] [Related]
20. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer.
Maas M; Beets-Tan RG; Lambregts DM; Lammering G; Nelemans PJ; Engelen SM; van Dam RM; Jansen RL; Sosef M; Leijtens JW; Hulsewé KW; Buijsen J; Beets GL
J Clin Oncol; 2011 Dec; 29(35):4633-40. PubMed ID: 22067400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
